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SUMMARY
The need for a vaccine(s) against cutaneous leishmaniasis and the populations at risk for whom such vaccines should be
developed are briefly discussed. The current human vaccine studies are reviewed, as are some experimental mouse studies
with emphasis on Leishtnania major infection relevant to vaccine development. Based on the information available from
the mouse model and those data which are being sought in human studies, the benign nature of the cutaneous disease,
the ease with which L. major can be manipulated to yield the required material, and the ongoing practice of leishmanization
which allows rapid evaluation of candidate vaccine(s), it is suggested that a vaccine, at least against L. major, is imminent
in the not too distant future.
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INTRODUCTION
It was the observation that milkmaids who recover
from cowpox are immune to infection with smallpox
that prompted Jenner to perform his bold human
experiment. Subsequently, cowpox virus ('vaccinia')
became a vaccine against smallpox and the term
' vaccination' was applied to the general practice of
immunization against an infective agent. Similarly,
the term ' leishmanization ' has recently been applied
to an ancient practice of deliberate infection with
Leishmania for the purpose of inducing a long-
lasting immunity against Old World Cutaneous
Leishmaniasis (OWCL) which often involves
multiple lesions in exposed areas of the body.
Clearly, this method of prophylactic immunization
is not without risk and difficulties, as will be
discussed later. However, in the absence of any other
feasible or practical control measures, leishman-
ization was used in the past in the USSR (Kellina,
personal communication) and Israel (Greenblatt,
1980, 1988) and is being used on a large scale in Iran
today (Nadim & Javadian, 1988).
There are several excellent review articles on
immunological studies of experimental leishmaniasis
(Behin & Louis, 1984; Liew, 1986; Blackwell,
McMahon-Pratt & Shaw, 1986; Mauel & Behin,
1987; also see a collection of articles edited by Louis
& Milon, 1987; Muller, Pedrazzini, Farrell & Louis,
1989). This report will therefore focus primarily on
ongoing human studies and those of the L. major
mouse model as they pertain to vaccine development.
WHO NEEDS A VACCINE?
An important issue to be considered for vaccine
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development is the population for whom vaccines
are required. At present chemotherapy with anti-
monial drugs is expensive, treatment is required for
a long time, produces side-effects, and is associated
with numerous relapses and refractory cases. Indeed,
it is not recommended to treat the zoonotic OWCL
cases caused by L. major, unless multiple disfiguring
or non-healing lesions are seen. The patients have no
choice but to accept the suffering from a 6—9 month
open ulcer(s) and the consequences of the non-
aesthetic scar(s) which are left for the remainder of
their lives. On the other side of the spectrum,
visceral leishmaniasis (VL) of the Old World caused
by L. donovani is presumably lethal if untreated once
the signs and symptoms of the disease are well
developed. In the visceral leishmaniasis (VL) caused
by L. chagasi (and possibly L. infantum) the infection
may be subclinical and self-healing in a relatively
large number of cases. In certain individuals,
perhaps due to factors like malnutrition, the infection
will develop into a progressive disease which will
require treatment (Badaro, Jones, Carvalho,
Sampaio, Reed, Barral, Teixeira & Johnson, 19866;
Badaro, Jones, Lorenco, Cerf, Sampaio, Carvalho,
Rocha, Teixeira & Johnson, 1986 c). Subclinical
infection with L. donovani has also been recognized
by Sacks, Lai, Shrivastava, Blackwell & Neva
(1987).
Amongst the most difficult cases to cure, are the
mucocutaneous (MCL) patients who cannot be
definitively cured even with high doses of anti-
monials given for prolonged periods (Marsden,
1986).
Not knowing all the risk factors involved in the
development of VL and MCL following the in-
fection, it is difficult to know whether a vaccine
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should be used for a general population living in an
endemic zone. The risks involved in injection of
foreign material as a vaccine to healthy individuals,
particularly children, must be carefully evaluated
against the risks of getting the disease and the
possible effects thereof. In addition, one must weigh
the feasibility and cost of other control measures
(to decrease the risk of disease) against those of
vaccination. So far, with the limited information
available, it seems that vaccination would be the
most practical control tool for certain populations, if
safe, effective and inexpensive vaccines were avail-
able. Certain groups have predictably a very high
risk factor, for example, workers on new develop-
ment projects, individuals from non-endemic
regions who move to a highly endemic area, and
children in hyperendemic regions where almost all
are eventually infected. This is particularly true for
zoonotic OWCL. These are obvious targets for
vaccination but others must be carefully evaluated.
HOW MANY VACCINES ARE NEEDED AGAINST
L E I S H M A N I A S E S ?
Leishmaniasis is often referred to as a ' spectral'
disease, because of the different clinical or patho-
logical forms in which it can be presented. Indeed,
some of the major forms (visceral and cutaneous)
may be considered as different diseases, for they are
normally caused by different species with completely
different pathology, vector and reservoir specificity
and ecology. Common features to all forms of
leishmaniases are (a) large number of common
antigens shared by different species, (b) all are
transmitted by female sandflies, (c) the sole target
cell in the mammalian host is believed to be the
macrophage and (d) generally, resistance to re-
infection by the same organism follows a successful
recovery from the original infection.
Despite the considerable antigenic cross-reactivity
amongst Leishmania species, recovery from an in-
fection does not confer immunity against others.
However, some cross-protection has been noted, e.g.
human infection with L. major is believed to produce
a protective response against L. tropica infection (but
not vice versa) and some experimental cross-re-
activity has been demonstrated (reviewed by Mauel,
1982; Alexander & Kaye, 1985; Mitchell &
Handman, 1987; Alexander, 1988).
Conceivably, a vaccine using some common
antigens of the parasites might be effective against all
forms of leishmaniases provided that they are
presented by the appropriate antigen-presenting
cells (APC) and can induce the protective T cell
response. Unfortunately the characteristics of the
antigens of different species of Leishmania presented
on the surface of APC are not known.
Alternatively, an immune response against the
common sandfly vectors which can enhance the
virulence of the inoculum, as described recently
(Titus & Ribeiro, 1988) may induce a transmission
blocking immunity which could be effective against
several forms. A factor has been identified which
closely resembles one of the peptides of the calci-
tonin-related gene products (CRGP). This peptide
produces a strong vasodilation and local inflam-
matory reaction, thereby providing monocytes,
target cells for Leishmania (Titus and Ribeiro, manu-
script submitted). These points are highly theoretical
and require further investigation.
VACCINE DESIGN
One might consider that most, if not all, effective
vaccines used in humans so far, have been developed
without knowing details of the mechanisms of
protection, or the nature of the protective antigen
(epitope). The empirical approach of vaccine develop-
ment, therefore, should not be totally abandoned
until vaccine design can be accomplished with the
new technology.
The Scientific Working Group on Leishmaniases
of the UNDP/World Bank/WHO Special Pro-
gramme on Research and Training in Tropical
Diseases (TDR) recommended that the Programme
should simultaneously pursue several approaches,
e.g. empirical approach using killed organisms for
prophylactic immunization (Mayrink, Williams, Da
Costa, Magalhaes, Melo, Dias, Lima, Michalick,
Carvalho, Barros, Sessa & de Alencar, 1985;
Antunes, Mayrink, Magalhaes, Costa, Melo, Dias,
Michalick, Williams, Lima, Vieira & Schettini,
1986), and with BCG, for immunotherapy (Convit,
Castellanos, Rondon, Pinardi, Ulrich, Castes, Bloom
& Garcia, 1987), semi-purified, or well-defined
preparations showing promise in animal studies
(Monjour, Ogunkolade, Pointet & Vouldoukis, 1985;
Handman & Mitchell, 1985, 1987; Monjour,
Ogunkolade, Vouldoukis, Roseto, Berneman &
Frommel, 1986; Frommel, Ogunkolade, Vouldoukis
& Monjour, 1988; Russell & Alexander, 1988; Scott,
Pearce, Nativitz & Sher, 1987) and genetically
engineered vaccine constructs which still require
some fundamental development.
WHAT KIND OF VACCINE IS NEEDED?
An important requirement for many vaccines is that
they must prevent infection. This may not be
necessary for a vaccine against leishmaniasis, as
discussed below, infection may exist without an
observable pathological manifestation and disease
prevention without interfering with infection may be
an advantage.
Experiments in mice of different genetic back-
ground infected with L. major (Leclerc, Modabber,
Deriaud & Chedid, 1981) indicated that the organism
remains viable in various organs long after the lesion
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is healed. One possible mechanism by which the
parasites can evade the immune responses of the host
is that they are able to hide within the 'safe targets'
(pre-granulocyte—macrophage cells), which increase
considerably during infection (Mirkovich, Galelli,
Allison & Modabber, 1986; Modabber, 1987). These
cells presumably cannot be activated to kill the
parasite (Hoover & Nacy, 1984).
In humans, cell-mediated immune responses per-
sist for many years following recovery from an
infection (Wyler, Weinbaum & Herrod, 1979). In
my personal case a very strong delayed-type
hypersensitivity (DTH) reaction to leishmanin as
measured by skin test, was observed 14 years after
living in a non-endemic area (almost 24 years after 3
lesions had healed). This strongly suggests that
antigens or parasites persisted for a very long time
after recovery from the infection. Furthermore an
increasing number of patients with acquired immune
deficiency syndrome (AIDS) or other form of
immune deficiency are being reported also to suffer
from recrudescent leishmaniasis (Badaro, Carvalho,
Rocha, Queiroz & Jones, 1986a; Martinez-
Fernandez, Diaz, Sanchez, Carmena, Varela &
Navas, 1987; Verdejo, Alvar, Polo & Lahoz, 1987;
Clauvel, Couderc, Belmin, Daniel, Rabian &
Seligman, 1986; Medrano-Gonzalez, Lorenzo &
Perez, 1986; Senaldi, Cadeo, Carnevale, Di Perri &
Carosi, 1986; Franco-Vicario, Heredia, Rojo &
Hermosa, 1987; Mulliez, Dabouz, Demory, Darras
& Crinquette, 1987; Antunes, Carvalho, Tavares,
Botas, Forte, Del Rio, Dutschmann, Costa,
Abranches, Pereira, Paiva, Araujo & Baptista, 1987).
It has been suggested that leishmaniasis should be
considered as an opportunistic disease (Badaro et al.
1986a).
All these observations indicate that at least in some
cases, leishmaniasis produces a state of premunition
(concurrent infection and immunity) which may be
the underlying mechanism for prolonged immunity
to reinfection generally seen in recovered indi-
viduals. Only when the immune response becomes
deficient can the disease relapse.
If this is true, then the vaccine does not have to
prevent infection to be disease-protective for the
general population. This reduces the stringent
requirements for a protective vaccine. In any case,
for those living in an endemic region where they are
continuously exposed to leishmanial antigens even a
vaccine which can produce a short-term immunity
may be sufficient when given at an appropriate
time.
The degree of immunity is generally related to the
dose of the virulent parasite given; while a low dose
may be tolerated without producing a lesion, a high
dose will overwhelm the immune response. Hence a
vaccine which can only reduce the effective dose of
the inoculum may be adequate for some populations
who develop some degree of natural immunity as a
result of repeated exposure to subinfective doses of
the parasite.
On the other hand, repeated infection with the
same organism has been reported in a few cases (e.g.
Killick-Kendrick, Bryceson, Peters, Evans, Leaney
& Rioux, 1985). This may represent an aberrant
immunological response induced by previous infec-
tions, genetic or other factors. Indeed, repeated
infection may occur but it is usually milder and
recovery is quicker. It must be noted that in highly
endemic regions, following recovery from a natural
infection, repeated infections are rare, at least in the
ZCL area.
Cutaneous leishmaniasis is the most frequently
occurring form of the disease and this is the form
which probably imposes the highest economic loss,
particularly in new development projects in the
Latin American countries and the Middle East. As
the disease is relatively benign and the immunity
produced following recovery from the original
infection is generally life-long for indigenous popu-
lations, the development of a vaccine seems the least
difficult compared to vaccines against other forms.
In certain populations of the ZCL-endemic areas,
almost 100% will eventually become infected and
age-related incidence remains predictably constant
for children. This, in addition to the programmes of
leishmanization, provides a special opportunity for
evaluation of candidate vaccines. All these points
indicate that a prophylactic vaccine against ZCL is
feasible, beneficial, cost-effective and needed for
those who live in or enter hyperendemic zones of
OWZCL.
Development of a vaccine(s) against other forms of
the disease, however, is not as simple and requires
much more detailed information on the pathology of
the disease, risk factors, etc.
An inexpensive vaccine which produces a life-long
protection after a single administration without any
side-effects would be ideal. Live vaccines which
establish a state of premunition require one admini-
stration and produce a long-lasting protection. As
Leishmania produce a state of premunition (shown in
animal models and implied by the recrudescent VL
in AIDS, patients without previous history of clinical
leishmaniasis as mentioned above), a live vaccine
should not be ruled out despite disappointing trials
in the past (Heyneman, 1971).
The failure of previous vaccine trials has been
attributed to changes of the parasite in culture, as
indicated by Mauel (1982). The stability of the
parasite must be assured in any vaccine development
strategy. Changes of the characteristics of the
parasites in culture have been re-examined elegantly
for many Leishmania species in recent years
(Giannini, 1974; Keithly & Bienen, 1981; Sacks &
Perkins, 1984; Franke, McGreevy, Katz & Sacks,
1985; Wozencraft & Blackwell, 1987; Melo, Wil-
liams, Magalhaes-Rocha, Baba, Mayrink, Michalick,
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Da Costa, Diaz & Magalhaes, 1987; Turco, Hull,
Orlandi, Sheperd, Homans, Dweck & Rademacher,
1987; Howard, Sayers & Miles, 1987; Celeste &
Guimaraes, 1988), and inhibition of one species by
another in a mixed culture has also been seen
(Pacheco, Grimaldi & Morel, 1987).
In addition, the isolate used for vaccination was
not cloned as methods for cloning had not been
developed and the possibility of a mixed Leishmania
culture being used as the original vaccine preparation
cannot be dismissed.
In recent years, biochemical and genetic analyses
of Leishmania spp. have provided a large number of
powerful tools and markers which can be used for
characterization and identification of parasites, and
to assure the stability of vaccines, whether a live or
non-living vaccine is used (Arnot & Barker, 1981;
Wirth & McMahon-Pratt, 1982; Jaffe & McMahon-
Pratt, 1983; Etges, Bouvier, Hoffman & Bordier,
1985; Blackwell, 1985; Chang, Inserra, Kink, Fong
& Chang, 1986; Button & McMaster, 1988; Puentes,
Sacks, Da Silva & Joiner, 1988).
The encouraging view of the prospects for a live
vaccine is based on experimental vaccination of
mice with non-pathogenic live clones of L. major
(Mitchell, Handman & Spithill, 1984). The
genetically engineered organism carrying genes of
protective antigens from different pathogens may
not be as far-fetched as it seemed a few years ago
(Jacobs, Tuckman & Bloom, 1987).
HUMAN VACCINATION
At present there are 3 ongoing studies in human
leishmaniasis. These employ living L. major (leish-
manization, Nadim & Javadian (1988)) ; a mixture of
killed whole organisms (Mayrink et al. 1985; Antunes
et al. 1986) and killed organisms plus BCG (Convit
et al. 1987). The last is being used for immuno-
therapy although it may be considered in the future
for prophylaxis.
These and the recent information gained from
studies on experimental animals are the basis for
renewed interest in pursuing vaccine development.
LEISHMANIZATION
The Iranian group has admitted to using leish-
manization because all other attempts to control the
disease in some communities had failed. As a result
of the success obtained in these communities leish-
manization was then used as a control method on a
large scale because of the very high incidence of ZCL
in and around the war zone border of Iran and Iraq.
Recruits and volunteers were given the live inoculum
about 3 months before being sent to endemic areas.
The inoculum, approximately 2-3 x lO 5 L. major in
01 ml of supernatant fluid of 10-15 day NNN
cultures was injected intradermally. The inoculum
Table 1. Leishmanization in Iran
(Data from Nadim & Javadian (1988).
Recipient: 1 200000 Soldiers
160000 Civilians around Isfahan
60000 Civilians, war refugees in
Khuzestan
Vaccine: 2-3 x 105 live virulent Leishmania major
(lesion of 5-10 mm for 4—6 months).
2-3 % large and non-healing lesions,
requiring treatment.
Evaluation in some selected villages (1982). Vaccinated*
(530), 14 infectedf (26%); non-vaccinated (1724), 250
infected (1415%).
* 77 % takes.
f Lesions were smaller and healed quicker than infected
individuals of non-vaccinated populations.
Skin test conversion = 93 % in 'takes', 54% in 'non-
takes ' from another study.
therefore contained all the material present in the
supernatant fluid of the medium, e.g. components of
rabbit blood, agar, and any product of the parasite.
According to the report of Nadim & Javadian
(1988), over 200000 civilians and 1-25 million
soldiers have received leishmanization within the
past 6 years. The analysis of data is incomplete (see
Table 1). However, it is reported that out of 8000
cases from the Isfahan area, 'less than 100' had
received leishmanization. In general, those who had
received inoculation had smaller lesions which
healed sooner. In other independent studies, 77 % of
inoculated individuals developed a lesion due to
inoculation (vaccine takes) and of these 93 % were
shown to produce a positive skin test. The skin test
was positive in 54% of non-takes (those who were
inoculated but did not develop a lesion).
The rate of skin test positivity in a normal
population of age- and sex-matched children was not
reported, but it must be much lower than this.
Needless to say this is not an acceptable control
method except in extremely critical situations in
which the incidence is very high and other methods
are impracticable or ineffective. The 'vaccine' itself
produces a lesion of 5-10 mm in diameter which
lasts an average of 4—6 months, if no complication is
produced. This is more than an acceptable side-
effect of many vaccines. Complications include large
non-healing lesions which may last for years,
requiring treatment, and immediate type hyper-
sensitivity reactions which may last for a few hours
with or without treatment. As the leishmanization
programme introduced individuals with an active
lesion to areas where CL was not present before
(soldiers returning home) and some indigenous cases
were subsequently reported, the question of initia-
ting new foci of transmission has been raised by
local authorities. If true (it seems unlikely), it would
mean that for L. major, human-sandfly-human
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Table 2. Killed disrupted parasites
(Two groups were analysed in 1981; only group 1 is
presented. In group 2, the difference in incidence was not
significant. In the 1983 study, the numbers were too small
and the difference was not significant. There was no
indication of exacerbation in previously immunized indi-
viduals in any of the studies. Data from Antunes et al.
(1986).)
Table 3. Immunotherapy compared to
chemotherapy
(Data from Convit et al. (1987).)
1981 trial
Vaccinated
Placebo
1983 trial
Vaccinated
Placebo
Skin test
Converted
Non-converted
Non-converted
Converted
Non-converted
Non-converted
Total
104
207
289
415
195
616
Cases
3
22
32
1
3
8
Incidence
(%)
2-9
10-6
111
0-2
1-5
1-3
transmission may occur. More detailed analysis of
the cases, the sandfly and particularly the parasite
and reservoir hosts is required to establish this.
KILLED LEISHMANIA OF THE NEW WORLD
After the historical studies using killed Leishmania in
the New World, Mayrink and his colleague (1985)
initiated a series of experiments which are the basis
of renewed interest in pursuing the development of
killed vaccine. As will be discussed later, based on
observations in mice, there was a theoretical concern
that in humans as well, the injection of killed
organisms may induce an exacerbating disease upon
subsequent infection. Although the Brazilian studies
were not decisive on the protective efficacy of the
vaccine, they established an important parameter
that, at least in the few infected cases and under the
experimental conditions used, there was no ex-
acerbation produced as a result of previous injection
of killed organisms.
A summary of the two trials is shown in Table 2,
only for the groups which had a statistically sig-
nificant difference in their incidence rates. The
incidence rates of the infection in both studies are
very low for evaluation of the efficacy of the vaccine.
The trial of 1981 was complicated by a proximal
vaccination (in time) with yellow fever vaccine which
may have had an immunosuppressive effect, possibly
accounting for the low rate of skin test conversion of
3 3 % as compared with the trial of 1983 which
produced a conversion rate of 84-90%, depending
upon the type of vaccine used. Although the skin test
reactivity does not have a causal relationship with
protection in mice, analysis of the data from 1981
studies by Antunes et al. (1986) suggests that the
skin test in humans may be an important indicator of
an immune response which fortuitously reflects a
state of protection.
Cure rate
(34 weeks) Side-effects
Immunotherapy (52) 94 5-8 (mild)
Chemotherapy (42) 94 52-4*
Vaccine - Leishmania mexicana (killed) + BCG
6-4 x 10s + varying doses of BCG.
Drug - Glucantime (50 mg/kg) 20 days x 3, 10 days rest
in between.
• Cardiovascular disturbance, bone and muscle pain,
hypertension and severe colitis.
The results of Brazilian studies open an avenue for
further investigations where the incidence of the
disease is high and an unequivocal result on the
efficacy of killed vaccines may be obtained.
KILLED LEISHMANIA PLUS BCG FOR
IMMUNOTHERAPY
Following the success of immunotherapy of patients
with leprosy, (Convit, Aranzazu, Ulrich, Pinardi,
Reyes & Alvarado, 1982), a similar procedure was
used for treatment of localized cutaneous leishman-
iasis, using killed L. mexicana with BCG. This
treatment was compared with chemotherapy using
meglumine antimonate (Glucantime). The results
from the first series of patients (Convit et al. 1987,
see Table 3), indicate that 3 vaccinations over a
course of 32 weeks gave a similar rate of cure as was
achieved with chemotherapy, but resulted in con-
siderably fewer severe side-effects. It was suggested
that immunotherapy is an inexpensive, low-risk
alternative to chemotherapy. These studies have
now been expanded and the effect of BCG vaccina-
tion alone has been shown to be less dramatic (about
41 % at 33 weeks as compared to 95 % with
combination immunotherapy (Convit et al., manu-
script submitted)). In addition, the immune re-
sponses generated following immunotherapy are
being analysed with the aim of identifying the
protective mechanism(s) induced by vaccination.
ANIMAL MODELS
Many animal models have been used for immuno-
logical and therapeutic studies such as; the hamster
with most Leishmania species; guinea-pig with
L. enriettii (see Behin & Louis, 1984); several non-
human primates with a variety of different Leish-
mania species (Lainson & Bray, 1966; Lainson &
Shaw, 1977; Christensen & Vasquez, 1981 ; Walton,
Harper & Neal, 1983; Dennis, Chapman, Hanson &
Lujan, 1985; Dennis, Lujan, Chapman & Hanson,
1986; Lujan, Dennis, Chapman & Hanson, 1986;
Githure, Reid, Benhazim, Anjili, Shatry &
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Hendricks, 1987; Peireira, Melo, Mayrink & De
Resende, 1988). Some of these studies are pertinent
to vaccine development but will not be considered
here. The bulk of information on immunology and
pathology of leishmaniasis has been obtained from
mouse models. This is because of the availability of
cell markers, inbred, congenic and now even trans-
genic mice, in addition to all other attributes which
have made the mouse the animal of choice for
laboratory experimentation.
The mouse
Several laboratories discovered independently that
the susceptibility of inbred mice to a given Leish-
mania species (infection caused by promastigotes)
varies considerably and is controlled genetically
(Kellina, 1973; Handman, Ceredig & Mitchell,
1979; Behin, Mauel & Sordat, 1979; Nasseri &
Modabber, 1979; Perez, Labrador & Torrealba,
1979; Howard, Hale & Liew, 1980a). Most inbred
mice are resistant to L. major infection (recover
spontaneously) and only a few, notably BALB/c
and its H-2 congenic strains are highly susceptible.
These mice exhibit visceral disease and invariably
die of a fulminating disseminated infection, even
with injections of a very small inoculum (e.g. 100
organisms) compared to the 106 organisms required
to give a small self-healing lesion in resistant mouse
strains. This exquisite susceptibility has fascinated
many investigators who have used the BALB/c—
L. major model to study the immunology and also
the chemotherapy of leishmaniasis. Unfortunately,
L. major infection in BALB/c mice cannot be con-
sidered a model for any of the human leishmaniases.
The visceralization and the associated signs
(changes in serum proteins, peripheral blood cells,
anergy to skin test antigens, splenohepatomegaly,
etc.) resemble human kala azar (Djoko-Tamnou,
Leclerc, Modabber & Chedid, 1981). However, a
large lesion is initially produced at the site of
inoculation and metastatic lesions develop sub-
sequently quite unlike the human disease. The
philosophy of using BALB/c mice for vaccine or
drug studies is that if BALB/c can be protected or
cured then so can the resistant mouse strains which
produce a benign self-healing disease similar to
human zoonotic cutaneous leishmaniasis (ZCL). The
danger is that some otherwise potentially useful
reagents (drugs or vaccines) may be undetected
because of the stringencies and peculiarities asso-
ciated with the BALB/c—L. major model.
Influenced by epidemiological impressions, resist-
ance to leishmaniasis has been attributed to cell-
mediated immunity as measured by the classical
DTH reaction in humans, using leishmanin (phenol-
killed Leishmania) in a skin test (Montenegro
reaction). Early experiments with T cell deprived
(irradiated, thymectomized and bone-marrow recon-
stituted) mice showed the involvement of T cells in
the pattern of the disease (Preston, Carter, Leuchars,
Davies & Dumonde, 1972). Mitchell et al. (1980)
clearly demonstrated the role that T cells play in
immunity. The lack of DTH in infected BALB/c
mice (Nasseri & Modabber, 1979; Howard, Hale &
Liew, 19806) and transfer of resistance together with
DTH, by use of T cells from protected mice
(reviewed by Mitchell, 1984), further pointed to a
correlative, if not a causal relationship between
DTH and resistance. In fact, in the era of dominance
of suppressor T cells in immunological phenomena,
the susceptibility of BALB/c mice was thought to be
due to the induction of suppressor T cells which
specifically down-regulated DTH response (Liew,
Hale & Howard, 1982). The first indication that
there was not a causal relation between DTH and
resistance was obtained from studies on F,X back-
cross of A/J x BALB/c mice infected with L.
major (Modabber, Alimohammadian, Khamesipour,
Pourmand, Kamali & Nasseri, 1980). The time of
death after infection did not correlate with the
presence or magnitude of the DTH response. The
elegant works of Louis and his collaborators (Lima,
Engers & Louis, 1984; Milon, Titus, Cerottini,
Marchal & Louis, 1986) and Liew, Howard & Hale,
(1984) clearly showed that DTH is not the protective
mechanism per se.
In the first successful immunization using killed
organisms, Howard, Nicklin, Hale & Liew (1982)
showed that intraperitoneal (i.p.) or intravenous
(i.v.) immunization with killed Leishmania rendered
BALB/c mice immune to L. major infection, yet the
mice at the time of challenge were DTH-negative.
The classical observation by Titus, Lima, Engers &
Louis (1984) that Leishmania-spec'ific T cell lines
which can activate infected macrophages to kill the
parasite in vitro will exacerbate the disease when
transferred in vivo, was surprising but crucial in the
understanding of the mechanism of the host-parasite
relationship. Not only did it become clear that in
vitro observations could not simply be extrapolated
to in vivo situations, but these findings showed that
activation of macrophages to kill intracellular para-
sites per se was not sufficient to control the disease.
Other factors, such as (a) different cytokines or (b)
parasite products, might override the crucial effector
mechanism, macrophage activation. Evidence for
both mechanisms exists: (a), firstly infected BALB/c
mice produce an inexplicably high concentration of
colony stimulating factors (CSF) and a high number
of granulocyte-macrophage colony forming cells
in culture (GM CFU-c, immature monocytes)
(Mirkovich et al. 1986). These premature cells act
as 'safe targets' for the parasite, presumably because
they cannot be activated to kill the parasites (Hoover
& Nacy, 1984). Titus et al. (1984) noted that exacer-
bating T cells induced accumulation of macrophages
at the site of the lesion, and also suggested that this
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may be a mechanism by which the disease is
exacerbated. In support of the 'safe target' hypo-
thesis are the observations that administration of
recombinant CSF (Solbach, Greil & Rollinghoff,
1987) or IL-3, multi-colony stimulating factor acting
on bone-marrow precursor cells (Feng, Louis,
Kindler, Pedrazzini, Eliason, Behin & Vassalli,
1988), will aggravate the disease in mice.
Alternatively, these lymphokines may directly
affect the mediators of macrophage activation, such
as gamma-interferon (IFN), as suggested by the
more recent results of Liew et al. (submitted for
publication). These investigators have presented
evidence indicating that the 'exacerbating' T cells
produce factors which can inhibit the IFN-mediated
activation of macrophages and thereby prevent
intracellular killing of Leishmania. The factors
involved are identified as interleukin 3 (IL-3) and
IL-4 (B cell stimulating factor also affects mast cell
differentiation). This observation is crucial for
explaining exacerbation of the disease in the presence
of large numbers of effector T cells in BALB/c mice
and the possible mechanism by which the un-
balanced T cell populations would lead to modi-
fication of the immune responses (reviewed by
Muller et al. 1989).
Recently, Kaufmann & Flesch (1988) have shown
that IL-4 and IL-5 (eosinophil differentiation factor)
potentiate the IFN-mediated activation of macro-
phages to kill Mycobacteria and other intracellular
organisms. This is an apparent contradiction with
the observations of Liew et al. (submitted). The
difference in the experimental design and the state of
'activation' required for killing bacteria versus
Leishmania may account for this apparent contra-
diction. The subdivision of T-helper (L3T4 + ) cells
into the two groups TH1 and TH2 on the basis of
lymphokine production (Mosmann & Coffman,
1987), provides an explanation for the dual and
contradictory roles described for L3T4+ Leish-
mania-specific T cells, mediating resistance as well
as abrogation of resistance (Liew et al. 1982; Titus,
Milon, Marshal, Vassali, Cerottini & Louis, 1987).
Disregarding some overlap between the two cell
types, TH1 and TH2 cells are distinguished by
production of IFN and IL-4, respectively. It follows
then that TH1 cells would be expected to protect and
TH2 cells to exacerbate. Indeed, Locksley, Heinzel,
Sadick, Holaday & Gardner (1987) have shown that
resistance in mice correlates with the ability to
produce THl- type cells.
Secondly, (6), parasite products may directly
interfere with the mechanism of activation of macro-
phages (Handman, Schnur, Spithill & Mitchell,
1986). It has been shown by Flesch & Kaufmann
(personal communication) that products of M. leprae
can suppress the IFN-mediated activation of bone-
marrow derived mononuclear phagocytes in vitro.
It is not known what factors influence the
induction of different subpopulations of cells. Opera-
tionally, the route of injection and the use of
adjuvants determine the predominant cell type
induced, for example, subcutaneous injection of
leishmanial antigens with Freund's complete ad-
juvant will lead to preferential induction of exacer-
bating cells (TH2), while i.v. or i.p. injections of
the parasite lead to predominant generation of
protective T cells (TH1). This may appear to be a
major problem in the development of human
vaccines. However, as mentioned above, numerous
studies in humans indicate that exposure to the
leishmanial antigens via the cutaneous route does not
sensitize the individual to produce an exacerbated
disease when subsequently infected with Leishmania
(Mayrink et al. 1985; Antunes et al. 1986; Nadim,
personal communication). More recently, Russell &
Alexander (1988) have shown that leishmanial anti-
gens, particularly the promastigote surface protease
(gp63) and the major surface glycoconjugate of
Handman, Greenblatt & Goding (1984), a com-
ponent of the excretory factor described by Schnur,
Zuckerman & Greenblatt (1972), could induce a
protective immune response when incorporated in
liposomes. This immunity was shown to be trans-
ferable by T cells. Hence presentation of antigen
can profoundly affect the ensuing immune responses.
The specificity of the protective cells (presumably
TH1) and the exacerbating L 3 T 4 + cells (pre-
sumably TH2) are not known. Is there a repertoire
restriction of epitope specificity ? This question is
obviously very important in developing molecularly
defined vaccines. If the specificity of T H 1 cells is
limited to certain antigenic moieties, then the choice
of molecules would be of crucial importance. On the
other hand, if there is no restriction with respect to
epitope specificity for TH1 and TH2, then a large
number of immunogenic molecules could be used
effectively, provided that they are presented in a
form (right vehicle, adjuvant, carrier and route of
injection) that can preferentially or exclusively
induce a TH1 response. Data to support both
arguments exist. According to Mitchell & Handman
(1986) the carbohydrate part of the LPG, is a
'suppressogenic' molecule - an unfortunate term
to denote a 'parasite-protective' molecule (a better
term used by the same authors) - e.g. a TH2-
stimulating immunogen, whereas the whole mole-
cule (LPG) would be a TH1-inducing and hence a
protective immunogen.
The mechanism of exacerbation produced by the
carbohydrate alone is not known, nor is the speci-
ficity of T cells produced after carbohydrate in-
jection. Do T cells recognize the carbohydrate, or is
the exacerbation mediated by B cells and their
products ? In other words, does the carbohydrate
moiety induce a TH2 response directly or via B
cells? It is known that carbohydrate immunogens
only stimulate antibody formation and not D T H .
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The protective effect of anti-/t treatment of BALB/c
(Sacks, Scott, Asofsky & Sher, 1984) is compatible
with a B cell-mediated susceptibility.
A more attractive hypothesis is that the nature of
the response is regulated by the antigen-presenting
cells (APC). In this model, the repertoire of T cell
specificity is not so limited as to exclude certain
groups of epitopes (including carbohydrate epi-
topes). Hence, if the epitope is presented properly
and all the required stimuli are available, the specific
T cell clone will be stimulated. The observation of
Russell & Alexander (1988) with gp63 in liposomes,
supports this notion. If so, then selection of mol-
ecularly defined potential vaccines would be easier
and would be based on their presence on those APC
which best induce a TH1 equivalent response in
humans. Several cell types are known to be APC, e.g.
macrophages, dendritic cells and B cells. Of these, it
is expected that B cells would not be the APC of
choice for a protective response against leish-
maniasis, for the reasons mentioned above. The
analysis of antigens presented by APC (other than B
cells) would be crucial in the selection of molecularly
defined vaccines.
One of the most important achievements of recent
years in the study of murine leishmaniasis is the
generation of T cell lines and clones which can
protect BALB/c mice against an otherwise lethal
challenge of L. major. This has been accomplished in
two laboratories independently. Muller & Louis
(submitted for publication, reviewed by Muller et al.
1989) have established two protective cell lines
which recognize only antigens associated with the
live Leishmania. These cells were generated in the
presence of live Leishmania, in contrast to the
previously generated T-cell lines and clones which
were all exacerbating and for which parasite extracts
were used. These authors believe that to be pro-
tective, T cells must recognize an antigen associated
with the live parasite, since the T cells must be able
to activate infected macrophages (containing live
parasites) in order to be protective. Otherwise T cells
which can only recognize antigens on the surface of
the macrophages which have ingested dead parasites,
could not be protective even if they are of the TH1
type. This model argues very strongly for the
importance of epitope specificity and imposes a new
requirement for TH1 cells in order to be protective.
Use of the TH1 versus TH2 model to explain the
diversity of functions by cells of the same phenotype
would still remain valid if macrophages which have
ingested dead parasites would also present some
antigens presented by the infected macrophages and
vice versa. It follows that only a proportion of TH1
cells would be involved in elimination of the
infection. This proportion depends on the number
of common antigens present on the surface of
macrophages which have ingested dead organisms
and the ones infected with the live parasites. The
analysis of antigens present on these two types of
macrophages is important.
Scott, Natovitz, Coffman, Pearce & Sher (1988)
have used a protective fraction of the parasite, which
they had identified previously (Scott et al. 1987), to
generate their protective line from which they have
produced a protective clone. These cells, in contrast
to those produced by Muller & Louis (1989),
mentioned above, will recognize the protective
fraction without requiring live parasites. It is not
known whether the antigen recognized is present on
the surface of infected macrophages, a feature which
would support Muller & Louis's model.
The protective fraction of Scott et al. (1988) may
contain the antigen or be the one that is also
presented on the surface of infected macrophages. On
the other hand, the specificity of the protective
clones of Muller and Louis may have been achieved
totally by chance and it may be that if many more
clones are produced, antigens common to infected
macrophages and macrophages that have ingested
dead parasites, or a fraction thereof, would be found.
Nevertheless, the specificity and functional analysis
of these and future protective cells will be needed to
understand the mechanism of immunity.
The requirements for an immunogen to be
protective, extrapolated from the mouse studies as
they are known today, seem to be the following.
First, the immunogen must be presented in such a
way that it would not produce a local inflammatory
reaction (see Titus & Ribero, 1988). Second, the
immunogen must be introduced so that it will be
presented by the appropriate APC which can induce
the desired immune responses (see Russell &
Alexander, 1987). Third, the immunogen must
induce predominantly, if not exclusively, a TH1
type T cell response, i.e. IFN-producing in the
mouse (see Locksley et al. 1987), or their equivalent
in the human, if they exist. These cells must
recognize an epitope on the surface of infected
macrophages, since activation of the infected macro-
phage is the necessary mechanism required for
killing of the intracellular parasites (see Muller et al.
1989). Fourth, the immunogen must not produce a
strong T or B cell stimulation (see Mitchell,
Handman, Moll, McConville, Spithall, Kidane,
Samaras & Elhay (1987) and Milon et al. (1986) on
enhanced T cell response, and Colle et al. (1983) and
Lohoff, Matzner & Rollingholl (1988) on polyclonal
B cell response).
With the information available, the ease with
which L. major can be cultured, the relatively benign
nature of cutaneous leishmaniasis and the possibility
of testing candidate immunogens in man, it is not
surprising that some of us ' Leishmaniacs' are very
optimistic and believe that if BALB/c mice can be
protected now, humans will be protected in the not
too distant future.
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182000072243
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:51:24, subject to the Cambridge Core terms of use, available at
Leishmaniasis vaccines S57
The author is indebted to Drs P. Castellanos, I. Flesch, J.
Louis, F. Y. Lievv, I. Muller, P. Scott and R. Titus for
providing unpublished data and/or manuscripts, and to
Mrs E. Borbor, Mrs M. Haegglund and Mr W. Keenan
for assisting with the manuscript and to Dr P. de Raadt
and Mr R. Modabber for reading it critically.
REFERENCES
ALEXANDER, j . (1988). Sex differences and cross-
immunity in DBA/2 mice with cutaneous leishmaniasis
correlates with the capacity to generate interleukin
3 in response to Leishmania antigen in vitro.
Cellular Immunology 111, 66-76.
ALEXANDER, j . & KAYE, p. M. (1985). Immunoregulatory
pathways in murine leishmaniasis: different regulatory
control during Leishmania mexicana mexicana and
Leishmania major infections. Clinical and Experimental
Immunology 61, 674-82.
ANTUNES, F., CARVALHO, C , TAVARES, L. BOTAS, J., FORTE,
M., DEL RIO, A. M., DUTSCHMANN, L., COSTA, A.,
ABRANCHES, P. , PEREIRA, C. S., PEIVA, J. E. D. ARAUJO,
F. c. & BAPTISTA, A. (1987). Visceral leishmaniasis
recrudescence in a patient with AIDS. Transactions of
the Royal Society of Tropical Medicine and Hygiene 81,
595.
ANTUNES, C. M. F., MAYRINK, W., MAGALHAES, P. A., COSTA,
A., MELO, M. N., DIAS, M., MICHALICK, M. S. M.,
WILLIAMS, P. , LIMA, A. O., VIERRA, J. B. F. & SCHETINI,
A. P. M. (1986). Controlled field trials of a vaccine
against New World cutaneous leishmaniasis.
International Journal of Epidemiology 15, 572-80.
ARNOT, D. E. & BARKER, D. c. (1981). Biochemical
identification of cutaneous leishmaniasis by analysis of
kinetoplast DNA. II. Sequence homologies in
Leishmania kDNA. Molecular Biochemistry and
Parasitology 3, 47-56.
BADARO, R., CARVALHO, E. M., ROCHA, H., QUEIROZ, A. C. &
JONES, T. c. (1986a). Leishmania donovani: an
opportunistic microbe associated with progressive
disease in three immunocompromised patients.
Lancet, i 647-8.
BADARO, R., JONES, T. C , CARVALHO, E. M., SAMPAIO, D.,
REED, S. G., BARRAL, A., TEIXEIRA, R. & JOHNSON, W. D. JR.
(1986/)). New perspectives on a subclinical form of
visceral leishmaniasis. Journal of Infectious Diseases
154, 1003-11.
BADARO, R., JONES, T. C , LORENCO, R., CERF, B. J.,
SAMPAIO, D., CARVALHO, E. M., ROCHA, H., TEIXEIRAS, R.
& JOHNSON, w. D., JR (1986c). A prospective study of
visceral leishmaniasis in an endemic area of Brazil.
Journal of Infectious Diseases 154, 639—49.
BEHIN, R. & LOUIS, j . (1984). Immune response to
Leishmania. Critical Reviews in Tropical Medicine 2,
141-88.
BEHIN, R., MAUEL, j . & SORDAT, B. (1979). Leishmania
tropica: pathogenicity and in vitro macrophage
function in strains of inbred mice. Experimental
Parasitology 48, 81-90.
BLACKWELL, j . M. (1985). Receptors and recognition
mechanisms of Leishmania species. Transactions of the
Royal Society of Tropical Medicine and Hygiene 79,
606-12.
BLACKWELL, J., McMAHON-PRATT, D. & SHAW, J. ( 1 9 8 6 ) .
Molecular biology of Leishmania. Parasitology Today
2, 45-54.
BUTTON, L. L. & MCMASTER, w. R. (1988). Molecular
cloning of the major surface antigen of Leishmania.
Journal of Experimental Medicine 167, 724—9.
CELESTE, B. j . & GUIMARAES, M. c. (1988). Growth curves
of Leishmania braziliensis braziliensis promastigotes
and surface antigen expression before and after
adaptation to Schneider's Drosophila medium as
assessed by anti-Leishmania human sera. Revista do
Instituto de Medicina Tropical de Sao Paulo 30, 63-7.
CHANG, C. S., INSERRA, T. J., KINK, H. A., FONG, D. &
CHANG, K. p. (1986). Expression and size heterogeneity
of a 63 kilodalton membrane glycoprotein during
growth and transformation of Leishmania mexicana
amazonensis. Molecular and Biochemical Parasitology
18, 197-210.
CHRISTENSEN, H. A. & VASQUEZ, A. M. ( 1 9 8 1 ) .
Susceptibility of Aotus trivirgatus to Leishmania
braziliensis and L. mexicana. American Journal of
Tropical Medicine and Hygiene 30, 54-6.
CLAUVEL, J. P. , COUDERC, L. J. , BELMIN, J., DANIEL, M. T.,
RABIAN, c. & SELIGMAN, M. (1986). Visceral
leishmaniasis complicating acquired immunodeficiency
syndrome (AIDS). Transactions of the Royal Society of
Tropical Medicine and Hygiene 80, 1010-11.
COLLE, J. H., TRUFFA-BACCHI, P., CHEDID, L. & MODABBER, F.
(1983). Lack of a general immunosuppression
during L. tropica infection in BALB/c mice:
augmented antibody response to thymo-independent
antigens and polyclonal activation. Journal of
Immunology 131, 1492-5.
CONVIT, J., ARANZAZU, N. , ULRICH, M., PINARDI, M. E.,
REYES, o. & ALVARADO, j . (1982). Immunotherapy with
a mixture of Mycobacterium leprae and BCG in
different forms of leprosy and Mitsuda-negative
contacts. International Journal of Leprosy 50, 415—24.
CONVIT, J., CASTELLANO, P. L. , RONDON, A., PINARDI, M. E. ,
ULRICH, M., CASTES, M., BLOOM, B. & GARCIA, L.
(1987). Immunotherapy versus chemotherapy in
localised cutaneous leishmaniasis. Lancet i 401-4.
DENNIS, V. A., CHAPMAN, W. L. JR., HANSON, W. L. &
LUJAN, R. (1985). Leishmania donovani: clinical,
hematologic and hepatic changes in squirrel monkeys
(Saimiri sciureus). Journal of Parasitology 71, 576—82.
DENNIS, V. A., LUJAN, R., CHAPMAN, W. L. JR. & HANSON,
w. L. (1986). Leishmania donovani: cellular and
humoral immune responses after primary and
challenge infections in squirrel monkeys, Saimiri
sciureus. Experimental Parasitology 61, 319—34.
DJOKO-TAMNOU, J., LECLERC, C , MODABBER, F. & CHEDID, L.
(1981). Studies on visceral Leishmania tropica
infection in BALB/c mice. 1. Clinical features and
cellular changes. Clinical Experimental Immunology 46,
493-8.
ETGES, R. J. , BOUVIER, J., HOFFMAN, R. & BORDIER, C.
(1985). Evidence that the major surface proteins of
three Leishmania species are structurally related.
Molecular and Biochemical Parasitology 14, 395-400.
FENG, Z. Y., LOUIS, J. A., KINDLER, V., PEDRAZZINI, T.,
EL1ASON, J., BEHIN, R. & VASSALLI, P. ( 1 9 8 8 ) .
Aggravation of experimental cutaneous leishmaniasis
in mice by administration of interleukin 3. European
Journal of Immunology 18, 1245-51.
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182000072243
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:51:24, subject to the Cambridge Core terms of use, available at
F. Modabber S58
FRANCO-VICARIO, R., DE HEREDIA, J. M. B., ROJO, P. &
HERMOSA, c. (1987). Leishmaniosis asociada al
sindrome de la immunodeficiencia acquirida.
Medicina Clinica 88, 565.
FRANKE, E. D., McGREEVY, P. B., KATZ, P. & SACKS, D. L.
(1985). Growth cycle-dependent generation of
complement-resistant Leishmania promastigotes.
Journal of Immunology 134, 2713-18.
FROMMEL, D., OGUNKOLADE, W., VOULDOUKIS, I. &
MONJOUR, L. (1988). Vaccine-induced immunity
against leishmaniasis in BALB/c mice. Injection and
Immunity 56, 843-8.
GIANNINI, M. s. (1974). Effects of promastigote growth
phase, frequency of subculture, and host age on
promastigote-initiated infections with Leishmania
donovani in the golden hamster. Journal of
Protozoology 21, 521-7.
GITHURE, J. I., REID, G. D. F., BENHAZIM, A. A., ANJILI, C. O.
SHATRY, A. M. & HENDRICKS, L. D. (1987).
Leishmania major : the suitability of East African
nonhuman primates as animal models for cutaneous
leishmaniasis. Experimental Parasitology 64, 438—47.
GREENBLATT, c. L. (1980). The present and future of
vaccination for cutaneous leishmaniasis. In New
Developments with Human and Veterinary Vaccines
(ed. A. Mizrahi, I. Hertman, M. A. Klinberg and
A. Kohn), pp. 259-85. New York: Alan R. Liss.
GREENBLATT, c. L. (1988). Cutaneous leishmaniasis: the
prospects for a killed vaccine. Parasitology Today 4,
53-4.
HANDMAN, E., CEREDIG, R. & MITCHELL, G. F. (1979).
Murine cutaneous Leishmaniasis: disease patterns in
intact and nude mice of various genotypes and
examination of some differences between normal and
infected macrophages. Australian Journal of
Experimental Biology and Medical Science 57, 9-29.
HANDMAN, E., GREENBLATT, C. L. & CODING, J. W. (1984).
An amphipathic sulphated glyucoconjugate of
Leishmania : characterization with monoclonal
antibodies. European Molecular Biology
Organization Journal 3, 2301-6.
HANDMAN, E. & MITCHELL, G. F. (1985). Immunization
with Leishmania receptor for macrophages protects
mice against cutaneous leishmaniasis. Proceedings of
the National Academy of Sciences, USA 5910-14.
HANDMAN, E. & MITCHELL, G. F. (1987). Leishmania-
macrophage interaction: role of parasite molecules in
infection and host protection. In Molecular Strategies
of Parasitic Invasion (ed. N. Agabian, H. Goodman
and M. Nogueira), pp. 493-500. New York: Alan K.
Liss.
HANDMAN, E., SCHNUR, L. F., SPITHILL, T. W. & MITCHELL,
G. F. (1986). Passive transfer of Leishmania
lipopolysaccharide confers parasite survival in
macrophages. Journal of Immunology 137, 3608-13.
HEYNEMAN, D. (1971). Immunology of leishmaniasis.
Bulletin of the World Health Organization 44,
499-514.
HOOVER, D. L. & NACY, c. A. (1984). Macrophage
activation to kill L. tropica : defective intracellular
killing of amastigotes by macrophages elicited with
sterile inflammatory agents. Journal of Immunology
132, 1487.
HOWARD, J. C , HALE, C. & LIEW, F. Y. ( 1 9 8 0 a ) .
Immunological regulation of experimental cutaneous
leishmaniasis. I. Immunogenetic aspects of
susceptibility to Leishmania tropica in mice.
Parasite Immunology 2, 303-14.
HOWARD, J. G., HALE, C. & LIEW, F. Y. (19806).
Immunological regulation of experimental cutaneous
leishmaniasis. III. The nature and significance of
specific suppression of cell-mediated immunity in
mice highly susceptible to L. tropica, Journal of
Experimental Medicine 152, 594-607.
HOWARD, J. G., NICKLIN, S., HALE, C. & LIEW, F. Y. (1982).
Prophylactic immunization against experimental
leishmaniasis. I. Protection induced in mice
genetically vulnerable to fatal Leishmania tropica
infection. Journal of Immunology 129, 2002-12.
HOWARD, K. M., SAYERS, G. & MILES, M. A. (1987).
Leishmania donovani metacyclic promastigotes:
transformation in vitro, lectin agglutination,
complement resistance and infectivity. Experimental
Parasitology 64, 147-56.
JACOBS, W. R. JR., TUCKMAN, M. & BLOOM, B. R. (1987).
Introduction of foreign DNA into mycobacteria using
a shuttle plasmid. Nature, London 327, 532-5.
JAFFE, c. & MCMAHON-PRATT, D. (1983). Monoclonal
antibodies specific for Leishmania tropica.
Journal of Immunology 131, 1987-93.
KAUFMANN, s. H. E. & FLESCH, I. E. A. Cell-mediated
immunity, immunodeficiency and microbial infections.
Current Topics in Infectious Diseases and Clinical
Microbiology (in the Press).
KELLINA, o. I. (1973). Differences of susceptibility of
inbred mice of different strains to L. tropica major.
Medical Parasitology 42, 279-80.
KEITHLY, j . A. & BIENEN, E. j . (1981). Infectivity of
Leishmania donovani primary culture promastigotes
for golden hamsters. Ada Tropica 38, 85-9.
KILLICK-KENDRICK, R., BRYCESON, A. D. M., PETERS, W.,
EVANS, D. A., LEANEY, A. J. & RIOUX, J.-A. (1985).
Zoonotic cutaneous leishmaniasis in Saudi Arabia:
lesions healing naturally in man followed by a second
infection with the same zymodeme. Transactions of the
Royal Society of Tropical Medicine and Hygiene 79,
363-5.
LAINSON, R. & BRAY, R. s. (1966). Studies on the
immunology and serology of leishmaniasis. II.
Cross-immunity experiments among different forms
of American cutaneous leishmaniasis in monkeys.
Transactions of the Royal Society of Tropical Medicine
and Hygiene 60, 526-32.
LAINSON, R. & SHAW, j . j . (1977). Leishmaniasis in Brazil.
XII. Observations on cross-immunity in monkeys and
man infected with Leishmania mexicana mexicana, L.
m. amazonensis, L. braziliensis braziliensis, L. b.
guyanensis, and L. b. panamensis. Transactions of the
Royal Society of Tropical Medicine and Hygiene 80,
29-35.
LECLERC, C , MODABBER, F., DERIAUD, F. & CHEDID, L.
(1981). Systemic infection of Leishmania tropica
(major) in various strains of mice. Transactions of the
Royal Society of Tropical Medicine and Hygiene 75,
851^.
LIEW, F. Y. (1986). Cell-mediated immunity in
experimental cutaneous leishmaniasis.
Parasitology Today 2, 264—70.
LIEW, F. Y., HALE, C. & HOWARD, J. G. (1982).
Immunologic regulation of experimental cutaneous
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182000072243
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:51:24, subject to the Cambridge Core terms of use, available at
Leishmaniasis vaccines S59
leishmaniasis. V. Characterization of effector and
specific suppressor T cells. Journal of Immunology
128, 1917-22.
LIEW, F. Y., HOWARD, j . c. & HALE, c. (1984). Prophylactic
immunization against experimental leishmaniasis. III.
Protection against fatal Leishmania tropica infection
induced by irradiated promastigotes involves
Lyt-1 +2-T cells that do not mediate cutaneous
DTH. Journal of Immunology 132, 456-61.
LIMA, c. C, ENGERS, H. D. & LOUIS, j . A. (1984). Adoptive
transfer of delayed type hypersensitivity reactions
specific for Leishmania major antigens to normal mice
using murine T-cell populations and clones generated
in vitro. Clinical and Experimental Immunology 576,
130-8.
LOCKSLEY, R. M., HEINZEL, F. P., SADICK, M. B., HOLADAY,
B. j . & GARDNER, K. D. JR., (1987). Murine cutaneous
leishmaniasis: susceptibility correlates with
differential expansion of helper T-cell subsets.
Twentieth Forum in Immunology, Annales de I'Institut
Pasteur/Immunologie 138, 744—9.
LOHOFF, M., MATZNER, C. & ROLLINGHOLL, M. ( 1 9 8 8 ) .
Polyclonal B-cell stimulation by L3T4 + T cells in
experimental leishmaniasis. Infection and Immunity 56,
2120-4.
LOUIS, j . & MILON, G. (1987). Immunology of
experimental leishmaniasis. Twentieth Forum in
Immunology, Annales de I'Institut Pasteur/Immunologie
138, 219-27.
MARSDEN, P. D. (1986). Mucosal leishmaniasis
('espundia' Escomel, 1911). Transactions of the Royal
Society of Tropical Medicine and Hygiene 80, 859-76.
MARTINEZ-FERNANDEZ, R., DIAZ, G. J. D., SANCHEZ, G. J.,
CARMENA, C. E., VARELA, L. & NAVAS, A. F. ( 1 9 8 7 ) .
Leishmaniasis visceral en pacientes adictos a drogos
por via parenteral, VIH positivos. Medicine Clinica
(Barcelona) 88, 509-11.
MAUEL, J. (1982). Recent advances in the immunology of
leishmanial infections (with particular reference to the
problem of vaccination). Pontificiae Academia
Scientiarum Scripta Varia 47, 91-112.
MAUEL, j . & BEHIN, R. (1987). Immunity: clinical and
experimental. In The Leishmaniases (ed. W. Peters and
R. Killick-Kendrik), vol. 2, pp. 731-91. London:
Academic Press.
MAYRINK, W., WILLIAMS, P., DA COSTA, C. A.,
MAGALHAES, P. A., MELO, M. N., DIAS, M., LIMA, A. O.,
MICHALICK, M. S. M., CARVALHO, E. F., BARROS, G. C ,
SESSA, P. A. & DE ALENCAR, J. E. ( 1 9 8 5 ) . A n
experimental vaccine against American dermal
leishmaniasis: experience in the State of Espirito
Santo, Brazil. Annals of Tropical Medicine and
Parasitology 79, 259-69.
MEDRANO GONZALEZ, F., LORENZO, A. A. & PEREZ, B. J. L.
(1986). Leishmaniosis visceral de curso fatal asociada
infeccion por HTLV-III. Medicina Clinica
(Barcelona) 87, 780-1.
MELO, M. N. , WILLIAMS, P., WILLIAMS, P., MAGALHAES-
ROCHA, N. M., BABA, E. H., MAYRINK, W., MICHALICK,
M. S. M., DA COSTA, C. A., DIAZ, M. & MAGALHAES, P. A.
(1987). The change of behaviour of two strains of
Leishmania after cultivation in a defined medium.
Memdrias do Instituto Oswaldo Cruz, Rio de Janeiro
82, 557-61.
MILON, G., TITUS, R. G., CEROTTINI, J. C , MARCHAL, G. &
LOUIS, j . A. (1986). Higher frequency of L. major-
specific L3T4 + T cells in susceptible mice as
compared with resistant CBA mice. Journal of
Immunology 136, 1467.
MIRKOVICH, G. F., GALELLI, A., ALLISON, A. C. &
MODABBER, F. (1986). Increased myelopoiesis during
L. major infection in mice: generation of 'safe target',
a possible way to evade the effector immune
mechanism. Clinical Experimental Immunology 64, 1-7.
MITCHELL, G. F. (1984). Host-protective immunity and
its suppression in a parasitic disease: murine
cutaneous leishmaniasis. Immunology Today 5, 224—6.
MITCHELL, G. F., CURTIS, J. M., HANDMAN, E. & McKENZlE,
I. F. c. (1980). Cutaneous leishmaniasis in mice:
disease patterns in reconstituted nude mice of several
genotypes infected with Leishmania tropica, Australian
Journal of Experimental Biology and Medical Science
58, 521-32.
MITCHELL, G. F. & HANDMAN, E. ( 1 9 8 6 ) . T h e
glycoconjugate derived from a L. major receptor for
macrophages is a suppressogenic, disease-promoting
antigen in murine cutaneous leishmaniasis.
Parasite Immunology 8, 255—63.
MITCHELL, G. F. & HANDMAN, E. ( 1 9 8 7 ) . Hetero logOUS
protection in murine cutaneous leishmaniases.
Immunology and Cell Biology 65, 387-92.
MITCHELL, G. F., HANDMAN, E. & SPITHILL, T. W. ( 1 9 8 4 ) .
Vaccination against cutaneous leishmaniasis in mice
using nonpathogenic cloned promastigotes of
Leishmania major and importance of route of injection.
Australian Journal of Experimental Biology and
Medical Science 62, 145-53.
MITCHELL, G. F., HANDMAN, E., MOLL, H., MCONVILLE,
M. J., SPITHILL, T. W., KIDANE, G. Z., SAMARAS, N. &
ELHAY, M. j . (1987). Resistance and susceptibility of
mice to Leishmania major : a view from Melbourne.
Annales de I'Institut Pasteur/Immunologie 138, 738-43.
MODABBER, F. (1987). A model for the mechanism of
sensitivity of BALB/c mice to L. major and
premunition in leishmaniases. Annales de I'Institut
Pasteur /Immunologie 38, 781-6.
MODABBER, F. Z., ALIMOHAMMADIAN, A., KHAMESIPOUR, A.,
POURMAND, M. H., KAMALI, M. H. & NASSERI, M.
(1980). Studies on the genetic control of visceral
leishmaniasis in BALB/c mice by L. tropica. In
Genetic Control of Natural Resistance to Infection and
Malignancy (ed. E. Skamene, P. A. L. Kongshaven
and S. M. Landy), pp. 29-37. New York: Academic
Press.
MONJOUR, L., OGUNKOLADE, W., POINTET, P. &
VOULDOUKIS, I. (1985). Parasitologie animale. Efficacite
de la vaccination de la souris C57 BL/6 contre
l'infection par differentes especes de Leishmania
Comptes Rendus de I'Acade'mie des Sciences, Paris 18,
803-6.
MONJOUR, L., OGUNKOLADE, W., VOULDOUKIS, I.,
ROSETO, A., BERNEMAN, A. & FROMMEL, D. ( 1 9 8 6 ) .
Immunoprophylaxis against Leishmania infection with
a semi-purified antigen. Transactions of the Royal
Society of Tropical Medicine and Hygiene 80, 1013.
MOSMANN, T. R. & COFFMAN, R. L. ( 1 9 8 7 ) . T w o t y p e s o f
mouse helper T cell clone. Implications for immune
regulation. Immunology Today 8, 223—7.
MULLER, I., PEDRAZZINI, T., FARRELL, J. P. & LOUIS, J.
(1989). T-cell responses and immunity to
experimental infection with Leishmania major. Annual
Review of Immunology 7 (in the Press).
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182000072243
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:51:24, subject to the Cambridge Core terms of use, available at
F. Modabber S60
MULLIEZ, PH. , DABOUZ, R., DEMORY, J . L., DARRAS, A. &
CRINQUETTE, j . (1987). Une observation de
leishmaniosa chez un malade traite par corticoides
pour sarcoidose. Medecine et Maladies Infectieuses 6/7,
412-13
NADIM, A. & JAVADIAN, E. (1988). Leishmanization in the
Islamic Republic of Iran. In Research on Control
Strategies for the Leishmaniases (ed. B. Walton, P. M.
Wijeyaretne and F. Modabber), pp. 336-9. Ottawa:
International Development Research Centre.
NASSERI, M. & MODABBER, F. (1979). Generalized
infection and lack of delayed hypersensitivity in
BALB/c mice infected with Leishmania tropica major.
Infection and Immunity 26, 611-14.
PACHECO, R. S., GRIMALDI, G. JR. & MOREL, C. M. ( 1 9 8 7 ) .
Inhibition of growth of Leishmania mexicana mexicana
by Leishmania mexicana amazonensis during ' in vitro'
co-cultivation. Memdrias do Instituto Oswaldo Cruz,
Rio de Janeiro 82, 537-42.
PEIREIRA, L. H. , MELO, A. L., MAYRINK, W. & DE RESENDE,
D. M. D. (1988). A marmoset model for some New
World dermatotropic leishmaniases. Parasitologia 30,
(in the Press).
PEREZ, H., LABRADOR, F. & TORREALBA, J. W. ( 1 9 7 9 ) .
Variations in the response of five strains of mice to .
Leishmania mexicana. International Journal for
Parasitology 9, 27.
PRESTON, P. M. , CARTER, R. L. , LEUCHARS, E., DAVIES,
A. j . s. & DUMONDE, D. c. (1972). Experimental
cutaneous leishmaniasis. III. Effects of thymectomy
on the course of infection of CBA mice with
Leishmania tropica. Clinical and Experimental
Immunology 10, 337-57.
PUENTES, S. M., SACKS, D. L., DA SILVA, P. & JOINER, K. A.
(1988). Complement binding by two developmental
stages of Leishmania major promastigotes varying in
expression of a surface lipophosphoglycan. Journal of
Experimental Medicine 167, 887-902.
RUSSELL, D. G. & ALEXANDER, j . (1988). Effective
immunization against cutaneous leishmaniasis with
defined membrane antigens reconstituted into
liposomes. Journal of Immunology 140, 1274—9.
SACKS, D. L., LAL, S. L., SHRIVASTAVA, S. N . , BLACKWELL, J.
& NEVA, F. A. (1987). An analysis of T-cell
responsiveness in Indian kala-azar. Journal of
Immunology 138, 908—13.
SACKS, D. L. & PERKINS, P. v. (1984). Identification of an
infective stage of Leishmania promastigotes. Science
223, 1417.
SACKS, D. L. , SCOTT, P . A., ASOFSKY, R. & SHER, F. A.
(1984). Cutaneous leishmaniasis in anti-IgM-treated
mice: enhanced resistance due to functional depletion
of a B-cell-dependent T cell involved in the
suppressor pathway. Journal of Immunology 132,
2072-7.
SCHNUR, L. F. , ZUCKERMAN, A. & GREENBLATT, C. L. ( 1 9 7 2 ) .
Leishmanial serotypes as distinguished by the gel
diffusion of factors excreted in vitro and in vivo.
Israel Journal of Medical Sciences 8, 932-42.
SCOTT, P . , NATOVITZ, P . , COFFMAN, R. L., PEARCE, E. &
SHER, A. (1988). Immunoregulation of cutaneous
leishmaniasis: T-cell lines which transfer protective
immunity or exacerbation belong to different TH
subsets and respond to distinct parasite antigens.
Journal of Experimental Medicine 168, 1675-84.
SCOTT, P . , PEARCE, E., NATOVITZ, P. & SHER, A. ( 1 9 8 7 ) .
Vaccination against cutaneous leishmaniasis in a
murine model. II. Immunologic properties of
protective and nonprotective subfractions of a soluble
promastigote extract. Journal of Immunology 139,
3118-25.
SENALDI, G., CADEO, G., CARNEVALE, G., DI PERRI, G. &
CAROSI, G. (1986). Visceral leishmaniasis as an
opportunistic infection. The Lancet i 1094.
SOLBACH, W., GREIL, J. & ROLLINGHOFF, M. ( 1 9 8 7 ) . A n t i -
infectious responses in Leishmania major-infected
BALB/c mice injected with recombinant
granulocyte-macrophage colony-stimulating factor.
Annales de I'Institut Pasteur/Immunologie 138, 759-62.
TITUS, R. G., LIMA, G. C , ENGERS, H. D. & LOUIS, J. A.
(1984). Exacerbation of murine cutaneous
leishmaniasis by adoptive transfer of parasite-specific
helper T-cell populations capable of mediating
L. major specific delayed type hypersensitivity.
Journal of Immunology 133, 1594-1600.
TITUS, R. G., MILON, G., MARCHAL, G., VASSALLI, P . ,
CEROTTINI, j . c. & LOUIS, j . A. (1987). Involvement of
specific Lyt-2 + T cells in the immunological control
of experimentally induced murine cutaneous
leishmaniasis. European Journal of Immunology 17',
1429-33.
TITUS, R. G. & RIBEIRO, j . (1988). Salivary gland lysates
from the sand fly Lutzomyia longipalis enhance
Leishmania infectivity. Science 239, 1306-8.
TURCO, S. J. , HULL, S. R., ORLANDI, P. A. JR., SHEPHERD,
S. D., HOMANS, S. W., DWEK, R. A. & RADEMACHER, T. W.
(1987). Structure of the major carbohydrate fragment
of the Leishmania donovani lipophosphoglycan.
Biochemistry 26, 6233-8.
VERDEJO, J. , ALVAR, J., POLO, R. M. & LAHOZ, G. J. M.
(1987). Leishmaniasis visceral asociada a anti-HTLV
III positive Revista Clinica Espanola 180, 221.
WALTON, B. C , HARPER III, J. & NEAL, R. A. ( 1 9 8 3 ) .
Effectiveness of allopurinol against Leishmania
braziliensis panamensis in Aotus trivirgatus. American
Journal of Tropical Medicine and Hygiene 32, 46-50.
WIRTH, D. & MCMAHON-PRATT, D. ( 1 9 8 2 ) . R a p i d
identification of Leishmania species by specific
hybridization of kinetoplast DNA in cutaneous
lesions. Proceedings of the National Academy of
Sciences, USA 79, 6999-7003.
WOZENCRAFT, A. o. & BLACKWELL, j . M. (1987). Increased
infectivity of stationary-phase promastigotes of
Leishmania donovani: correlation with enhanced C3
binding capacity and CR3-mediated attachment to
host macrophages. Immunology 60, 559-63.
VVYLER, D. J., WEINBAUM, F. I. & HERROD, H. R. ( 1 9 7 9 ) .
Characterization of in vitro proliferative responses of
human lymphocytes to leishmanial antigens. Journal
of Infectious Diseases 140, 215-21.
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182000072243
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:51:24, subject to the Cambridge Core terms of use, available at
